Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells

International Journal of Cancer

Volumn 129, Issue 11, 2011, Pages 2566-2576

  Lopez, Tania V ^a   Lappin, Terence R J ^b   Maxwell, Perry ^b   Shi, Zhanzhong ^b,d   Lopez Marure, Rebeca ^c   Aguilar, Cecilia ^a   Rocha Zavaleta, Leticia ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^d KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

cervical cancer; erythropoietin; JAK STAT; proliferation

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; SMALL INTERFERING RNA; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER;

ANIMALS; APOPTOSIS; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CELL PROLIFERATION; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASES; MICE; MICE, NUDE; PARACRINE COMMUNICATION; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 80053337283     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25935     Document Type: Article

References (40)

1. Koury MJ, Bondurant MC,. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248: 378-81.
2. Klingmuller U, Bergelson S, Hsiao JG, Lodish HF,. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci USA 1996; 93: 8324-8. (Pubitemid 26269556)
3. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL, Krystal G,. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 1995; 14: 5557-68.
4. Kirito K, Nakajima K, Watanabe T, Uchida M, Tanaka M, Ozawa K, Komatsu N,. Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Blood 2002; 99: 102-10.
5. Farrell F, Lee A,. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004; 9 (Suppl 5): 18-30. (Pubitemid 39658342)
6. Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ,. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004; 214: 243-51. (Pubitemid 39207986)
7. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X,. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005; 166: 823-30. (Pubitemid 40315639)
8. Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ, Feldman L,. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 2009; 7: 1150-7.
9. Yasuda T, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, Mori S, Matsuo T, Nakamura Y,. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001; 106 (2 Suppl 2): 215-22.
10. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A,. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003; 162: 1789-806. (Pubitemid 36613038)
11. Leo C, Horn LC, Rauscher C, Hentschel B, Liebmann A, Hildebrandt G, Hockel M,. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 2006; 12: 6894-900. (Pubitemid 44974481)
12. Shenouda G, Mehio A, Souhami L, Duclos M, Portelance L, Belenkov A, Chow T,. Erythropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer 2006; 16: 752-6.
13. Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W,. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008; 122: 1005-11. (Pubitemid 351213997)
14. Goldberg MA, Glass GA, Cunningham JM, Franklin Bunn H,. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 1987; 84: 7972-6. (Pubitemid 17162815)
15. Fraser JK, Lin F-K, Berridge MV,. Expression and modulation of specific, high affinity binding sites for erythropoietin on the human erythroleukemic cell line K562. Blood 1988; 71: 104-9. (Pubitemid 18050398)
16. Jeong J-Y, Feldman L, Solar P, Szenajch J, Sytkowski AJ,. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 2008; 122: 274-80. (Pubitemid 350234712)
17. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TRJ,. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 2010; 8: 615-26.
18. Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-60. (Pubitemid 37009952)
19. Lambin P, Ramaekers Bram LT, van Mastrigt Ghislaine APG, van den Ende P, de Jong J, de Ruysscher Dirk KM, Pijls-Johannesma M,. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 2009; 8: CD006158.
20. Temkin SM, Hellmann M, Serur E, Lee YC, Abulafia O,. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer 2006; 16: 1855-61. (Pubitemid 44470046)
21. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P,; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-70. (Pubitemid 46127840)
22. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG,. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892-5. (Pubitemid 43289368)
23. Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, Johnston PG, Lappin TR,. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 2007; 25: 718-22. (Pubitemid 46354231)
24. Kirkeby A, van Beek J, Nielsen J, Leist M, Helboe L,. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods 2007; 164: 50-8. (Pubitemid 46935964)
25. Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, Kassner PD, Watson JE, Arnold GE, Nguyen KC, Powers S, Elliott S,. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008; 98: 1059-67. (Pubitemid 351399799)
26. Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N, Okamura K,. Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 2002; 8: 441-6. (Pubitemid 34567922)
27. Suzuki M, Takamizawa S, Nomaguchi K, Suzu S, Yamada M, Igarashi T, Sato I,. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol 2001; 113: 49-51. (Pubitemid 32423301)
28. Yokoyama Y, Shinohara A, Hirokawa M, Maeda N,. Erythrocytosis due to an erythropoietin-producing large uterine leiomyoma. Gynecol Obstet Invest 2003; 56: 179-83. (Pubitemid 37505845)
29. Pollio F, Staibano S, Mansueto G, de Rosa G, Persico F, de Falco M, Di Lieto A,. Erythropoietin and erythropoietin receptor system in a large uterine myoma of a patient with myomatous erythrocytosis syndrome: possible relationship with the pathogenesis of unusual tumor size. Hum Pathol 2005; 36: 120-7. (Pubitemid 40215642)
30. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y,. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002; 23: 1797-805. (Pubitemid 35355929)
31. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagano M, Sasaki R, Nakamura Y,. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2010; 84: 836-43.
32. Katsuoka Y, McGonigle R, Rege AB, Beckman B, Fisher JW,. Erythropoietin production in human renal carcinoma cells passaged in nude mice and in tissue culture. Gann 1983; 74: 534-41. (Pubitemid 13003643)
33. Mannello F, Fabbri L, Ciandrini E, Tonti GA,. Increased levels of erythropoietin in nipple aspirate fluid and in ductal cells from breast cancer patients. Cell Oncol 2008; 30: 51-61. (Pubitemid 351161038)
34. Hamadmad SN, Hohl RJ,. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. J Pharmacol Exp Ther 2008; 324: 1227-33. (Pubitemid 351397840)
35. Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, Devic S, Chow TY,. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004; 3: 1525-32. (Pubitemid 40136707)
36. Mirmohammadsadegh A, Marini A, Gustrau A, Delia D, Nambiar S, Hassan M, Hengge UR,. Role of erythropoietin receptor expression in malignant melanoma. J Invest Dermatol 2010; 130: 201-10.
37. Wierenga AT, Vogelzang I, Eggen BJ, Vellenga E,. Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol 2003; 31: 398-405. (Pubitemid 36579365)
38. Kirito K, Uchida M, Yamada M, Miura Y, Komatsu N,. A distinct function of STAT proteins in erythropoietin signal transduction. J Biol Chem 1997; 272: 16507-13. (Pubitemid 27276478)
39. Kirito K, Nagashima T, Ozawa K, Komatsu N,. Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells. Int J Hematol 2002; 75: 51-4. (Pubitemid 43014038)
40. Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T, Kage M, Hori D, et al,. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 2009; 101: 967-72.